Study 1 (Leonardi C et al. 2015): A Phase III, multicentre (US), double-blind, vehicle-controlled, 4-week study. Treatment success was defined as clear or almost clear skin (for patients with ≥moderate disease at baseline) or clear skin (for patients with mild disease at baseline), according to PGA. 53.3% (n=172/323) of patients using Enstilar® achieved treatment success by week 4 vs. 4.8% (n=5/103) of patients using foam vehicle (OR, 30.3; 95% CI, 9.7 to 94.3; P<0.001).
Study 2 (Koo J et al. 2016): A Phase II, multicentre, investigator-blinded study. Treatment success was defined as patients who achieved clear or almost clear skin with at least a two-step improvement according to the PGA scale. 54.6% (n=77/141) of patients using Enstilar® achieved treatment success by week 4 vs. 43.0% (n=58/135) of patients using calcipotriol/ betamethasone ointment (OR, 1.7; 95%CI, 1.1 to 2.8; P=0.025).
CI, confidence interval; OR, odds ratio; PGA, physician’s global assessment.